Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 55 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMACIE D'OTTIGNIES from Ottignies-Louvain-la-Neuve, company number BE0442281693, closed financial year 2025 with a result of € 145,480 after tax. For that financial year PHARMACIE D'OTTIGNIES recorded a gross margin of € 318,019 and equity of € 344,059. Compared with financial year 2024, the result moved from € 72,600 to € 145,480. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 7, 2026.
€ 344,059
▲ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 145,480
▲ 100% vs 2024
Profit after tax over the fiscal year.
€ 87,974
▲ 10% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 124,000 paid out
85 % of the profit went to the shareholders, mostly to SV PHARMA (100 % of the shares). That is where the money ends up.
People and assets in 2025
1.5
▲ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 112,072
▲ 27% vs 2024
€ 74,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 7,885
▲ 13% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 27,372
▼ 13% vs 2024
€ 4,182 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 174,868
▲ 3% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 21,620
▲ 10% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 229,837 | € 169,663 | € 212,609 | € 318,019 | ▲ 50% |
| Profit after taxes | € 128,912 | € 74,811 | € 72,600 | € 145,480 | ▲ 100% |
| Equity | € 315,168 | € 319,979 | € 322,578 | € 344,059 | ▲ 7% |
| Total debts | € 325,810 | € 379,713 | € 317,490 | € 374,920 | ▲ 18% |
| Cash | € 145,265 | € 120,589 | € 79,925 | € 87,974 | ▲ 10% |
| Retained profit | € 234,168 | € 238,979 | € 241,578 | € 263,059 | ▲ 9% |
| Dividend | € 50,000 | € 70,000 | € 70,000 | € 124,000 | ▲ 77% |
| Bank debt | € 90,065 | € 66,596 | € 31,372 | € 27,372 | ▼ 13% |
| Balance sheet total | € 640,978 | € 699,692 | € 640,068 | € 718,979 | ▲ 12% |
| Employees (FTE) | 1.1 | 0 | 1.3 | 1.5 | ▲ 0.2 |
Key figures of PHARMACIE D'OTTIGNIES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMACIE D'OTTIGNIES?
What happened at PHARMACIE D'OTTIGNIES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Antoine Stil stepped down as director. NBB
- Anne Scarnier stepped down as director. NBB
- SV PHARMA SRL stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 145,480 (▲ 100% vs 2024). filed late Source: NBB ↗
- Antoine Stil became a director. NBB
- Anne Scarnier became a director. NBB
- SV PHARMA SRL became a director. NBB
- New establishment in Ottignies-Louvain-la-Neuve. KBO
In short
From € 128,912 profit in 2022 to € 145,480 profit in 2025.
Paid € 131,029 in corporate taxes since 2022.
Best year ever: 2025, with € 145,480 profit.
On average € 212,000 of value added per employee in 2025.
A new publication or filing at PHARMACIE D'OTTIGNIES? We notify you, reason included.
Follow PHARMACIE D'OTTIGNIESDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by SV PHARMA (100%).
Directors
According to the 2025 annual accounts
since 2021 · until 2027
Anne Scarnier
Director
since 2021 · until 2027
Director · represented by Damien Vanden Berghe
since 2021 · until 2027
Shareholders
SV PHARMA · holding of Antoine Stil
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Avenue Reine Astrid 24
1340 Ottignies-Louvain-la-Neuve
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0442.281.693
- VAT number
- BE 0442.281.693
- Registered office
- Avenue Reine Astrid 24, 1340 Ottignies-Louvain-la-Neuve
- Names & denominations
- PHARMACIE D'OTTIGNIES
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 11 December 1990
- Peppol
- Active · Active since 4 Sept 2025
- Activities · NACE
Apothekers
Detailhandel in farmaceutische producten